Exane Derivatives Neurocrine Biosciences Inc Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Exane Derivatives holds 1,084 shares of NBIX stock, worth $132,475. This represents 0.07% of its overall portfolio holdings.
Number of Shares
1,084
Previous 3
36033.33%
Holding current value
$132,475
Previous $0
Infinity%
% of portfolio
0.07%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding NBIX
# of Institutions
622Shares Held
95.2MCall Options Held
661KPut Options Held
221K-
Black Rock Inc. New York, NY14.2MShares$1.73 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.23 Billion0.03% of portfolio
-
State Street Corp Boston, MA4.61MShares$563 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.47MShares$302 Million0.6% of portfolio
-
Jpmorgan Chase & CO New York, NY2.36MShares$289 Million0.03% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.7B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...